Status:
TERMINATED
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Pancreatic Neoplasm
Pituitary Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
Eligibility Criteria
Inclusion
- Male and Female Patients at least 18 years old
- Patient who have rare tumors of neuroendocrine origin, such as tumors of the:
- pancreas
- pituitary glands
- Nelson syndrome
- ectopic-ACTH secreting tumor
- Patients who have failed standard of care treatment or for whom no standard of care treatment exist
- Signed Informed Consent
Exclusion
- Patients with active gallbladder disease
- Patients with any ongoing or planned anti-neoplastic or interferon therapy
- Poorly controlled diabetes mellitus
- Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT00958841
Start Date
September 1 2009
End Date
June 1 2015
Last Update
July 26 2016
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars Sinai Medical Center Cedars Sinai 4
Los Angeles, California, United States, 90048
2
Cedars Sinai Medical Center The Pituitary Center (3)
Los Angeles, California, United States, 90048
3
Stanford University Medical Center SC
Stanford, California, United States, 94304
4
Dana Farber Cancer Institute Deptof DanaFarberCancerInst(5)
Boston, Massachusetts, United States, 02215